Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Value Line Small Cap Opportunities Fund Stephen E. Grant | “Chemed was liquidated entirely during the first quarter as part of a portfolio refinement program. The manager sought to redirect assets away from lower-conviction names.” | BEAR | Q1 2026 Mar 31, 2026 | View Pitch |
Aristotle Small Cap Equity Fund Jack McPherson and Dave Adams | “Chemed (CHE), engages in the provision of healthcare and maintenance services operating through two segments: VITAS and Roto-Rooter. The VITAS segment offers hospice and palliative care services to patients through a network of health care providers, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The stock declined due to concerns surrounding the potential Medicare cap limits proposed in current legislation for its VITAS segment alongside weaker residential demand for its plumbing services segment. We continue to maintain our position, as we believe the slowing demand in the Roto-Rooter segment is transitory and the secular demand for hospice care remains strong. BSD Analysis: Chemed is a strange beast: part hospice powerhouse (VITAS), part plumbing and restoration royalty (Roto-Rooter) — and both are quietly excellent businesses. Hospice demand grows as the population ages and care shifts from hospitals to lower-cost settings, and VITAS has scale and clinical depth that smaller operators lack. Roto-Rooter, meanwhile, is an all-weather cash machine — when something breaks, people don't “wait for macro to improve,” they just pay. The portfolio looks odd, but the cash-flow profile is outstanding: recurring, diversified, and recession-resistant. Management has historically been disciplined in capital allocation and buybacks. Chemed is the kind of name you own for a decade and forget about — until you notice how much it compounded.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
